Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 970

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 10
Chunk 970
---
-3

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENT OF OPERATIONS

FOR THE PERIOD FROM MAY 23, 2024 (INCEPTION)
THROUGH DECEMBER 31, 2024

    General and administrative costs 
    $279,845 
  
    Net Loss 
    $(279,845)

    Weighted average shares outstanding, basic and diluted (1)(2) 
     8,571,429 

    Basic and diluted net loss per ordinary shares 
    $(0.03)

  (1) Includes an aggregate of up to 1,285,714 ordinary shares subject to surrender and forfeiture if the over-allotment option is not exercised in full by the underwriters (Note 5). In February 2025 the over-allotment option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 9).  (2) On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Company for no consideration, following which the Sponsor holds 9,857,143 ordinary shares (the “Founder Shares”). All share and per share data has been retrospectively presented. 

The accompanying notes are an integral part
of the financial statements.

F-4

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENT OF CHANGES IN SHAREHOLDERS’
DEFICIT

FOR THE PERIOD FROM MAY 23, 2024 (INCEPTION)
THROUGH DECEMBER 31, 2024

    Ordinary Shares  
    Additional Paid-in  
    Accumulated  
    Total Shareholders’ 

    Shares  
    Amount  
    Capital  
    Deficit  
    Deficit 
  
    Balance — May 23, 2024 (inception) 
     —  
    $—  
    $—  
    $—  
    $— 

    Issuance of Founder Shares to Sponsor(1)(2) 
     9,857,143  
     986  
     34,014  
     —  
     35,000 

    Net loss 
     —  
     —  
     —  
     (279,845) 
     (279,845)

    Balance — December 31, 2024 
     9